

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: December 28, 2019
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-14041

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of
incorporation or organization)

04-2882273
(I.R.S. Employer
Identification No.)

125 Summer Street
Boston,
Massachusetts
(Address of principal executive offices)

02110
(Zip Code)

(781) 848-7100

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Exchange on Which Registered
Common stock, \$.01 par value per share	HAE	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes No x

The number of shares of \$0.01 par value common stock outstanding as of January 31, 2020: 50,298,046

HAEMONETICS CORPORATION
INDEX

	<u>PAGE</u>
<u>PART I. FINANCIAL INFORMATION</u>	
<u>ITEM 1. Financial Statements</u>	
<u>Unaudited Condensed Consolidated Statements of Income and Comprehensive Income - Three and Nine Months Ended December 28, 2019 and December 29, 2018</u>	<u>3</u>
<u>Unaudited Condensed Consolidated Balance Sheet - December 28, 2019 and Audited Consolidated Balance Sheet - March 30, 2019</u>	<u>4</u>
<u>Unaudited Condensed Consolidated Statements of Stockholders' Equity - Three and Nine Months Ended December 28, 2019 and December 29, 2018</u>	<u>5</u>
<u>Unaudited Condensed Consolidated Statements of Cash Flows - Nine Months Ended December 28, 2019 and December 29, 2018</u>	<u>7</u>
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	<u>8</u>
<u>ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>22</u>
<u>ITEM 3. Quantitative and Qualitative Disclosures about Market Risk</u>	<u>33</u>
<u>ITEM 4. Controls and Procedures</u>	<u>33</u>
<u>PART II. OTHER INFORMATION</u>	<u>34</u>
<u>ITEM 1. Legal Proceedings</u>	<u>34</u>
<u>ITEM 1A. Risk Factors</u>	<u>34</u>
<u>ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>34</u>
<u>ITEM 3. Defaults upon Senior Securities</u>	<u>35</u>
<u>ITEM 4. Mine Safety Disclosures</u>	<u>35</u>
<u>ITEM 5. Other Information</u>	<u>35</u>
<u>ITEM 6. Exhibits</u>	<u>36</u>
<u>SIGNATURES</u>	<u>37</u>

ITEM 1. FINANCIAL STATEMENTS

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Unaudited in thousands, except per share data)

	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
Net revenues	\$ 258,970	\$ 247,356	\$ 749,987	\$ 718,284
Cost of goods sold	130,920	136,181	379,031	411,958
Gross profit	128,050	111,175	370,956	306,326
Operating expenses:				
Research and development	7,000	8,978	21,909	26,967
Selling, general and administrative	78,267	73,877	221,106	219,670
Impairment of assets	1,876	—	50,597	—
Total operating expenses	87,143	82,855	293,612	246,637
Operating income	40,907	28,320	77,344	59,689
Interest and other expense, net	(3,078)	(2,858)	(12,152)	(7,875)
Income before provision for income taxes	37,829	25,462	65,192	51,814
Provision for income taxes	7,934	7,185	6,290	17,630
Net income	\$ 29,895	\$ 18,277	\$ 58,902	\$ 34,184
Net income per share - basic	\$ 0.59	\$ 0.36	\$ 1.16	\$ 0.66
Net income per share - diluted	\$ 0.58	\$ 0.35	\$ 1.13	\$ 0.64
Weighted average shares outstanding				
Basic	50,630	51,401	50,810	51,708
Diluted	51,638	52,822	51,995	53,184
Comprehensive income	\$ 32,296	\$ 13,214	\$ 55,577	\$ 24,079

The accompanying notes are an integral part of these condensed consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited in thousands, except share data)

	December 28, 2019	March 30, 2019
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 126,417	\$ 169,351
Accounts receivable, less allowance of \$4,097 at December 28, 2019 and \$3,937 at March 30, 2019	170,753	185,027
Inventories, net	254,167	194,337
Prepaid expenses and other current assets	31,238	27,406
Total current assets	582,575	576,121
Property, plant and equipment, net	268,104	343,979
Intangible assets, less accumulated amortization of \$287,526 at December 28, 2019 and \$263,479 at March 30, 2019	107,307	127,693
Goodwill	211,062	210,819
Deferred tax asset	4,428	4,359
Other long-term assets	64,273	11,796
Total assets	\$ 1,237,749	\$ 1,274,767
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Notes payable and current maturities of long-term debt	\$ 61,966	\$ 27,666
Accounts payable	52,298	63,361
Accrued payroll and related costs	44,425	53,200
Other liabilities	98,003	91,532
Total current liabilities	256,692	235,759
Long-term debt, net of current maturities	309,738	322,454
Deferred tax liability	14,576	19,906
Other long-term liabilities	82,163	28,780
Total stockholders' equity		
Common stock, \$0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,390,614 shares at December 28, 2019 and 51,019,918 shares at March 30, 2019	504	510
Additional paid-in capital	537,913	536,320
Retained earnings	69,868	161,418
Accumulated other comprehensive loss	(33,705)	(30,380)
Total stockholders' equity	574,580	667,868
Total liabilities and stockholders' equity	\$ 1,237,749	\$ 1,274,767

The accompanying notes are an integral part of these condensed consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited in thousands)

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders' Equity
	Shares	Par Value				
Balance, March 30, 2019	51,020	\$ 510	\$ 536,320	\$ 161,418	\$ (30,380)	\$ 667,868
Employee stock purchase plan	25	—	1,830	—	—	1,830
Exercise of stock options	85	1	3,634	—	—	3,635
Shares repurchased	(616)	(6)	(21,473)	(53,521)	—	(75,000)
Issuance of restricted stock, net of cancellations	257	3	(3)	—	—	—
Share-based compensation expense	—	—	4,730	—	—	4,730
Net loss	—	—	—	(8,479)	—	(8,479)
Other comprehensive loss	—	—	—	—	(3,618)	(3,618)
Balance, June 29, 2019	50,771	\$ 508	\$ 525,038	\$ 99,418	\$ (33,998)	\$ 590,966
Exercise of stock options	64	1	2,409	—	—	2,410
Shares repurchased	(360)	(4)	1,274	(51,270)	—	(50,000)
Issuance of restricted stock, net of cancellations	133	1	(1)	—	—	—
Share-based compensation expense	—	—	5,000	—	—	5,000
Net income	—	—	—	37,486	—	37,486
Other comprehensive loss	—	—	—	—	(2,108)	(2,108)
Balance, September 28, 2019	50,608	\$ 506	\$ 533,720	\$ 85,634	\$ (36,106)	\$ 583,754
Employee stock purchase plan	20	1	1,537	—	—	1,538
Exercise of stock options	60	—	1,667	—	—	1,667
Shares repurchased	(411)	(4)	(4,335)	(45,661)	—	(50,000)
Issuance of restricted stock, net of cancellations	114	1	(1)	—	—	—
Share-based compensation expense	—	—	5,325	—	—	5,325
Net income	—	—	—	29,895	—	29,895
Other comprehensive income	—	—	—	—	2,401	2,401
Balance, December 28, 2019	50,391	\$ 504	\$ 537,913	\$ 69,868	\$ (33,705)	\$ 574,580

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders' Equity
	Shares	Par Value				
Balance, March 31, 2018	52,343	\$ 523	\$ 503,955	\$ 266,942	\$ (18,991)	\$ 752,429
Employee stock purchase plan	45	1	1,779	—	—	1,780
Exercise of stock options	75	1	2,830	—	—	2,831
Shares repurchased	(888)	(9)	(4,552)	(75,439)	—	(80,000)
Issuance of restricted stock, net of cancellations	67	—	—	—	—	—
Share-based compensation expense	—	—	3,379	—	—	3,379
Cumulative effect of change in accounting principles	—	—	—	1,177	—	1,177
Net loss	—	—	—	(2,819)	—	(2,819)
Other comprehensive loss	—	—	—	—	(4,719)	(4,719)
Balance, June 30, 2018	51,642	\$ 516	\$ 507,391	\$ 189,861	\$ (23,710)	\$ 674,058
Exercise of stock options	125	1	4,294	—	—	4,295
Shares repurchased	(182)	(2)	14,213	(14,211)	—	—
Issuance of restricted stock, net of cancellations	40	1	—	—	—	1
Share-based compensation expense	—	—	4,582	—	—	4,582
Net income	—	—	—	18,726	—	18,726
Other comprehensive loss	—	—	—	—	(323)	(323)
Balance, September 29, 2018	51,625	\$ 516	\$ 530,480	\$ 194,376	\$ (24,033)	\$ 701,339
Employee stock purchase plan	22	—	1,474	—	—	1,474
Exercise of stock options	66	1	2,320	—	—	2,321
Shares repurchased	(771)	(7)	(7,924)	(72,069)	—	(80,000)
Issuance of restricted stock, net of cancellations	51	—	(1)	—	—	(1)
Share-based compensation expense	—	—	4,782	—	—	4,782
Net income	—	—	—	18,277	—	18,277
Other comprehensive loss	—	—	—	—	(5,063)	(5,063)
Balance, December 29, 2018	50,993	\$ 510	\$ 531,131	\$ 140,584	\$ (29,096)	\$ 643,129

The accompanying notes are an integral part of these condensed consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited in thousands)

	Nine Months Ended	
	December 28, 2019	December 29, 2018
Cash Flows from Operating Activities:		
Net income	\$ 58,902	\$ 34,184
Adjustments to reconcile net income to net cash provided by operating activities:		
Non-cash items:		
Depreciation and amortization	81,524	79,637
Impairment of assets	50,597	21,170
Share-based compensation expense	15,055	12,743
Deferred tax benefit	(4,747)	12,330
Provision for losses on accounts receivable and inventory	(2,246)	3,220
Gain on sale of assets	(8,083)	—
Other non-cash operating activities	1,945	1,038
Change in operating assets and liabilities:		
Change in accounts receivable	13,807	(19,752)
Change in inventories	(68,251)	(11,624)
Change in other assets and other liabilities	(9,102)	(231)
Change in accounts payable and accrued expenses	(17,590)	5,928
Net cash provided by operating activities	111,811	138,643
Cash Flows from Investing Activities:		
Capital expenditures	(38,112)	(105,245)
Proceeds from divestiture	9,808	—
Proceeds from sale of property, plant and equipment	16,263	2,314
Net cash used in investing activities	(12,041)	(102,931)
Cash Flows from Financing Activities:		
Net increase in short-term loans	30,000	—
Term loan borrowings	—	347,780
Repayment of term loan borrowings	(8,750)	(258,103)
Share repurchases	(175,000)	(160,000)
Proceeds from employee stock purchase plan	3,368	3,254
Proceeds from exercise of stock options	7,712	9,446
Other	90	—
Net cash used in financing activities	(142,580)	(57,623)
Effect of exchange rates on cash and cash equivalents	(124)	(3,387)
Net Change in Cash and Cash Equivalents	(42,934)	(25,298)
Cash and Cash Equivalents at Beginning of Period	169,351	180,169
Cash and Cash Equivalents at End of Period	\$ 126,417	\$ 154,871
Supplemental Disclosures of Cash Flow Information:		
Interest paid	\$ 10,739	\$ 9,492
Income taxes paid	\$ 9,888	\$ 6,233
Non-Cash Investing and Financing Activities:		
Transfers from inventory to fixed assets for placement of Haemonetics equipment	\$ 10,705	\$ 12,100
Right-of-use assets and lease incentive acquired	\$ 41,826	\$ —

The accompanying notes are an integral part of these condensed consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation ("Haemonetics" or the "Company") presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company's management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Certain immaterial reclassifications have been made to prior years' amounts to conform to the current year's presentation. Operating results for the nine months ended December 28, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 28, 2020 or any other interim period. The Company has assessed its ability to continue as a going concern. As of December 28, 2019, the Company has concluded that substantial doubt about its ability to continue as a going concern does not exist. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the annual report on Form 10-K for the fiscal year ended March 30, 2019.

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required for the three and nine months ended December 28, 2019 and are disclosed in Note 17, *Subsequent Event*.

2. RECENT ACCOUNTING PRONOUNCEMENTS

Standards Implemented

In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") Update No. 2016-02, *Leases (Topic 842)*. ASC Update No. 2016-02 is intended to increase the transparency and comparability among organizations by recognizing lease asset and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. In July 2018, the FASB issued an update to the leasing guidance to allow an additional transition option which would allow companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented. The Company adopted the new standard on March 31, 2019.

Upon transition, the Company applied the package of practical expedients permitted under ASC Update No. 2016-02 transition guidance to its entire lease portfolio at March 31, 2019. As a result, the Company is not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. The Company also elected to account for each lease component and the associated non-lease components as a single lease component and also elected not to recognize a lease liability or right-of-use asset for any lease that, at commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.

As a result of adopting ASC Update No. 2016-02, the Company recognized additional right-of-use assets of \$22.9 million and corresponding liabilities of \$22.7 million for its existing lease portfolio on the condensed consolidated balance sheets, with no material impact to the condensed consolidated statements of operations or condensed consolidated statements of cash flows. Additionally, the Company implemented a new lease administration and lease accounting system and has updated controls and procedures for maintaining and accounting for its lease portfolio under the new standard.

In March 2017, the FASB issued ASC Update No. 2017-07, *Compensation - Retirement Benefits (Topic 715)*. The guidance revises the presentation of net periodic pension cost and net periodic post-retirement benefit cost. The Company adopted ASC Update No. 2017-07 during the first quarter of fiscal 2020. The adoption of ASC Update No. 2017-07 did not have a material impact on the Company's condensed consolidated financial statements.

In June 2018, the FASB issued ASC Update No. 2018-07, *Compensation - Stock Compensation (Topic 718)*. The new guidance aligns the accounting for non-employee share-based payments with the existing employee share-based transactions guidance.

The Company adopted ASC Update No. 2018-07 during the first quarter of fiscal 2020. The adoption of ASC Update No. 2018-07 did not have a material impact on the Company's financial position and results of operations.

3. RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

In July 2019, the Board of Directors of the Company approved a new Operational Excellence Program (the "2020 Program") and delegated authority to the Company's management to determine the detail of the initiatives that will comprise the program. The 2020 Program is designed to improve operational performance and reduce cost principally in our manufacturing and supply chain operations. The Company estimates that it will incur aggregate charges between \$60 million and \$70 million in connection with the 2020 Program. These charges, the majority of which will result in cash outlays, including severance and other employee costs, will be incurred as the specific actions required to execute these initiatives are identified and approved and are expected to be substantially completed by the end of fiscal 2023. During the three and nine months ended December 28, 2019, the Company incurred \$3.9 million and \$6.8 million, respectively, of restructuring and turnaround costs under this program. Total cumulative charges under this program are \$6.8 million.

During fiscal 2018, the Company launched a Complexity Reduction Initiative (the "2018 Program"), a company-wide restructuring program designed to improve operational performance and reduce cost, freeing up resources to invest in accelerated growth. During the three and nine months ended December 28, 2019, the Company incurred \$3.9 million and \$6.8 million, respectively, of restructuring and turnaround costs under this program. During the three and nine months ended December 29, 2018, the Company incurred \$1.9 million and \$7.3 million, respectively, of restructuring and turnaround costs under this program. Total cumulative charges under this program are \$57.0 million.

The following table summarizes the activity for restructuring reserves for the nine months ended December 28, 2019, substantially all of which relates to employee severance and other employee costs:

<i>(In thousands)</i>	2020 Program	2018 Program and Prior Programs
Balance at March 30, 2019	\$ —	\$ 7,479
Costs incurred, net of reversals	1,409	1,520
Payments	(966)	(6,440)
Non-cash adjustments	—	(147)
Balance at December 28, 2019	<u>\$ 443</u>	<u>\$ 2,412</u>

As of December 28, 2019, the Company had a restructuring liability of \$2.9 million, of which \$2.4 million is payable within the next twelve months.

The following presents the restructuring costs by line item within our accompanying condensed consolidated statements of income and comprehensive income:

<i>(In thousands)</i>	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
Cost of goods sold	\$ 2	\$ —	\$ 444	\$ —
Research and development	139	56	708	112
Selling, general and administrative expenses	476	(750)	1,777	(1,131)
	<u>\$ 617</u>	<u>\$ (694)</u>	<u>\$ 2,929</u>	<u>\$ (1,019)</u>

In addition to the restructuring costs included in the table above, the Company also incurred costs that do not constitute restructuring under ASC 420, *Exit and Disposal Cost Obligations*, which the Company refers to as turnaround costs. These costs, substantially all of which have been included as a component of selling, general and administrative expenses in the accompanying condensed consolidated statements of income, consist primarily of expenditures directly related to the

restructuring actions and include program management costs associated with the implementation of outsourcing initiatives and recent accounting standards.

The tables below present restructuring and turnaround costs by the Company's three reportable segments as well as the Company's other corporate restructuring and turnaround costs:

Restructuring costs	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
<i>(In thousands)</i>				
Plasma	\$ 4	\$ 47	\$ 552	\$ (36)
Blood Center	18	6	154	51
Hospital	58	132	295	(91)
Corporate	537	(879)	1,928	(943)
Total	\$ 617	\$ (694)	\$ 2,929	\$ (1,019)
Turnaround costs	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
<i>(In thousands)</i>				
Plasma	\$ 108	\$ 80	\$ 187	\$ 123
Blood Center	293	182	293	182
Hospital	—	(68)	—	(207)
Corporate	6,780	2,254	10,173	8,142
Total	\$ 7,181	\$ 2,448	\$ 10,653	\$ 8,240
Total restructuring and turnaround costs	\$ 7,798	\$ 1,754	\$ 13,582	\$ 7,221

4. DIVESTITURE

On May 21, 2019, the Company transferred to CSL Plasma Inc. (“CSL”) substantially all of its tangible assets held relating to the manufacture of anti-coagulant and saline (together, “Liquids”) at its Union, South Carolina facility (“Union”), which consist primarily of property, plant and equipment and inventory, and CSL assumed certain related liabilities (the “Asset Transfer”) pursuant to the terms of a settlement, release and asset transfer agreement between the parties dated May 13, 2019. The Asset Transfer excludes all other assets related to Union, including accounts receivable, customer contracts and the Company’s U.S. Food and Drug Administration (“FDA”) product approvals for manufacturing Liquids.

At closing, Haemonetics received \$9.8 million of proceeds for the Asset Transfer and was concurrently released from its obligations to supply Liquids under a 2014 supply agreement with CSL. In connection with the Asset Transfer, CSL and Haemonetics also entered into related transition services, supply and manufacturing services and quality agreements that, among other things, permit CSL to manufacture Liquids under the Company’s FDA product approvals, exclusively for Haemonetics and CSL, until CSL obtains independent product approvals from the FDA to manufacture the Liquids.

In connection with the Company’s and CSL’s entry into the May 13, 2019 agreement for the Asset Transfer, the Company recognized a pre-tax impairment charge of \$48.7 million in the first quarter of fiscal 2020, primarily related to the carrying balances of the property, plant and equipment exceeding the consideration received under the terms of the Agreement. The charge will not result in any future cash expenditures.

5. INCOME TAXES

The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate is impacted by the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate.

For the three and nine months ended December 28, 2019, the Company reported an income tax provision of \$7.9 million and \$6.3 million, respectively, representing an effective tax rate of 21.0% and 9.6%, respectively. The effective tax rate for the three and nine months ended December 28, 2019 includes discrete tax benefits recognized from excess stock compensation deductions of \$3.1 million and \$12.4 million, respectively. The effective tax rates were also impacted by the jurisdictional mix

of earnings and the impact of the divestiture of the Union liquid solutions operation in the first quarter of fiscal 2020. Refer to Note 4, *Divestiture*, for additional details related to the divestiture of the Union liquid solutions operation.

For the three and nine months ended December 29, 2018, the Company reported an income tax provision of \$7.2 million and \$17.6 million, representing an effective tax rate of 28.2% and 34.0%, respectively. The tax rate for the three and nine months ended December 29, 2018 includes a discrete stock compensation windfall benefit of \$1.8 million and \$5.8 million, respectively. The effective tax rate for the nine months ended December 29, 2018 was higher than the U.S. statutory tax rate primarily due to an asset impairment of \$21.2 million recorded in pretax income for which no tax benefit was recognized as a result of the valuation allowance maintained against its deferred tax assets in the impacted jurisdiction.

6. EARNINGS PER SHARE ("EPS")

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.

	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
<i>(In thousands, except per share amounts)</i>				
Basic EPS				
Net income	\$ 29,895	\$ 18,277	\$ 58,902	\$ 34,184
Weighted average shares	50,630	51,401	50,810	51,708
Basic income per share	<u>\$ 0.59</u>	<u>\$ 0.36</u>	<u>\$ 1.16</u>	<u>\$ 0.66</u>
Diluted EPS				
Net income	\$ 29,895	\$ 18,277	\$ 58,902	\$ 34,184
Basic weighted average shares	50,630	51,401	50,810	51,708
Net effect of common stock equivalents	1,008	1,421	1,185	1,476
Diluted weighted average shares	51,638	52,822	51,995	53,184
Diluted income per share	<u>\$ 0.58</u>	<u>\$ 0.35</u>	<u>\$ 1.13</u>	<u>\$ 0.64</u>

Basic earnings per share is calculated using the Company's weighted-average outstanding common stock. Diluted earnings per share is calculated using its weighted-average outstanding common stock including the dilutive effect of stock awards as determined under the treasury stock method. For both the three and nine months ended December 28, 2019, weighted average shares outstanding, assuming dilution, excludes the impact of 0.2 million anti-dilutive shares. For the three and nine months ended December 29, 2018, weighted average shares outstanding, assuming dilution, excludes the impact of 0.2 million and 0.1 million anti-dilutive shares, respectively.

Share Repurchase Program

In May 2019, the Company's Board of Directors authorized the repurchase of up to \$500 million of Haemonetics common shares over the next two years.

In July 2019, the Company completed a \$75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement ("ASR") entered into with Citibank N.A. ("Citibank") in June 2019. The total number of shares repurchased under the ASR was 0.6 million at an average price per share upon final settlement of \$116.33.

In October 2019, the Company completed an additional \$50.0 million repurchase of its common stock pursuant to an ASR entered into with Morgan Stanley & Co. LLC ("Morgan Stanley") in September 2019. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of \$124.37.

In December 2019, the Company entered into an ASR with Bank of America, N.A. ("Bank of America") to repurchase \$50.0 million of the Company's common stock. Pursuant to the terms of the ASR, in December 2019, the Company paid Bank of America \$50.0 million in cash and received an initial delivery of 0.3 million shares of the Company's common stock based on a closing market price on the New York Stock Exchange on December 11, 2019 of \$117.55. This initial delivery of shares represented approximately 80% of the notional amount of the ASR. On January 23, 2020, the ASR was completed and an additional 0.1 million shares were delivered upon settlement. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of \$114.73.

As of December 28, 2019, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was \$325 million.

7. REVENUE

The Company's revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 606, *Revenue from Contracts with Customers*. Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of the Company's goods or services. The Company considers revenue to be earned when all of the following criteria are met: it has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the consideration it expects to receive for transferring goods or providing services, is determinable and it has transferred control of the promised items to the customer. A promise in a contract to transfer a distinct good or service to the customer is identified as a performance obligation. A contract's transaction price is allocated to each performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of the Company's contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation based on the estimated standalone selling prices of the good or service in the contract. For goods or services for which observable standalone selling prices are not available, the Company uses an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation.

As of December 28, 2019, the Company had \$22.1 million of its transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 56% of this amount as revenue within the next twelve months and the remaining balance thereafter.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the condensed consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities.

As of December 28, 2019 and March 30, 2019, the Company had contract assets of \$8.0 million and \$5.6 million, respectively. The change is primarily due to the delay in billings compared to the revenue recognized. Contract assets are classified as other current assets and other long-term assets on the condensed consolidated balance sheets.

As of December 28, 2019 and March 30, 2019, the Company had contract liabilities of \$17.4 million and \$20.3 million, respectively. During the three and nine months ended December 28, 2019, the Company recognized \$3.1 million and \$16.5 million, respectively, of revenue that was included in the above March 30, 2019 contract liability balance. Contract liabilities are classified as other liabilities and other long-term liabilities on the condensed consolidated balance sheets.

8. INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.

<i>(In thousands)</i>	December 28, 2019	March 30, 2019
Raw materials	\$ 73,834	\$ 69,420
Work-in-process	11,628	12,610
Finished goods	168,705	112,307
Total inventories	<u>\$ 254,167</u>	<u>\$ 194,337</u>

9. PROPERTY, PLANT AND EQUIPMENT

In December 2018, the Company entered into a lease for office space in Boston, MA to serve as its new corporate headquarters and replace its prior corporate headquarters located in Braintree, MA. As a result of this lease agreement, the Company received a lease incentive in the form of property, plant and equipment totaling \$5.6 million which was recorded upon commencement of the lease term in October 2019. Refer to Note 11, *Leases*, for additional information regarding this lease.

During the second quarter of fiscal 2020, the Company sold \$7.8 million of real estate and other assets associated with the Braintree corporate headquarters and entered into a lease with the buyer that allowed the Company to leaseback the facility on a rent-free basis through December 31, 2019 until the completion of its relocation to Boston, MA, which occurred during the third quarter of fiscal 2020. As a result of this transaction, the Company received net cash proceeds of \$15.0 million and non-cash consideration of \$0.9 million related to a free rent period ending in December 2019. The transaction resulted in a net gain of \$8.1 million.

During the first quarter of fiscal 2019, the Company recorded impairment charges of \$21.2 million, which consisted of \$19.8 million of charges related to the discontinued use of the HDC filter media manufacturing line and \$1.4 million of charges related to non-core and underperforming assets. These impairments were included within cost of goods sold on the condensed consolidated statements of income and impacted the Blood Center reporting segment.

10. GOODWILL AND INTANGIBLE ASSETS

Subsequent to the annual goodwill impairment test performed in the fourth quarter of fiscal 2019, the Company revised the composition of its reportable segments to align with its three global business units, Plasma, Blood Center and Hospital. Refer to Note 15, *Segment and Enterprise-Wide Information*, for additional information regarding the change in the Company's reportable segments.

A reporting unit is defined as an operating segment or one level below an operating segment, referred to as a component. The Company aggregates components within an operating segment that have similar economic characteristics. Consistent with its reportable segments, reporting units for purposes of assessing goodwill impairment have also been reorganized based on business unit and include: Plasma, Blood Center and Hospital.

To determine the amount of goodwill within each of the new reporting units, the Company reallocated, on a relative fair value basis, \$84.0 million of goodwill previously allocated to the former Europe, APAC and Japan reporting units to the new global reporting units. In addition, the \$126.8 million of goodwill previously allocated to the former North America reporting units was reallocated to each new respective global reporting unit.

The following represents our goodwill balance by new global reportable segment. The prior period information has been restated to conform to the current presentation:

<i>(In thousands)</i>	Plasma	Blood Center	Hospital	Total
Carrying amount as of March 30, 2019	\$ 28,828	\$ 37,319	\$ 144,672	\$ 210,819
Currency translation	—	50	193	243
Carrying amount as of December 28, 2019	\$ 28,828	\$ 37,369	\$ 144,865	\$ 211,062

11. LEASES

Lessee Activity

The Company has operating leases for office space, land, warehouse and manufacturing space, R&D laboratories, vehicles and certain equipment. Finance leases are not significant. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of 1 year to approximately 30 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to the Company's adoption of ASC 842, the Company measured the

lease liabilities and right-of-use assets using the incremental borrowing rate as of March 31, 2019. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

During the third quarter of fiscal 2020, the Company entered into a lease for office space in Boston, MA to serve as its new corporate headquarters and completed the relocation to this new office from its previous corporate headquarters located in Braintree, MA. The lease term associated with the new corporate headquarters extends through June 30, 2032 and includes two five year renewal options. During the third quarter of fiscal 2020, the Company recorded a right-of-use asset of \$36.2 million and corresponding liabilities of \$41.8 million upon commencement of the lease term in October 2019. In addition, the Company recorded \$5.6 million of property, plant and equipment as a result of a lease incentive received associated with this lease agreement.

The following table presents supplemental balance sheet information related to the Company's operating leases:

<i>(In thousands)</i>	December 28, 2019
Assets	
Operating lease right-of-use assets in <i>Other long-term assets</i>	\$ 54,158
Liabilities	
Operating lease liabilities in <i>Other current liabilities</i>	\$ 5,947
Operating lease liabilities in <i>Other long-term liabilities</i>	\$ 54,446

The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:

	December 28, 2019
Weighted average remaining lease term	10.1 Years
Weighted average discount rate	4.00%

During the three and nine months ended December 28, 2019 the Company's operating lease cost was \$3.8 million and \$8.4 million, respectively.

The following table presents supplemental cash flow information related to our operating leases:

<i>(In thousands)</i>	Three Months Ended December 28, 2019	Nine Months Ended December 28, 2019
Cash paid for amounts included in the measurement of operating lease liabilities		
Operating cash flows used for operating leases	\$ 1,326	\$ 5,160

The following table presents the maturities of our operating lease liabilities as of December 28, 2019:

<i>Fiscal Year (In thousands)</i>	Operating Leases
2020 (excluding the first nine months of 2020)	\$ 1,528
2021	9,484
2022	8,322
2023	7,422
2024	5,678
Thereafter	40,962
Total future minimum operating lease payments	73,396
Less: imputed interest	(13,003)
Present value of operating lease liabilities	\$ 60,393

Assets on the Company's balance sheet classified as Haemonetics equipment primarily consists of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represents less than 3 percent of the Company's total net sales.

12. NOTES PAYABLE AND LONG-TERM DEBT

On June 15, 2018, the Company entered into a credit agreement with certain lenders which provided for a \$350.0 million term loan (the "Term Loan") and a \$350.0 million revolving loan (the "Revolving Credit Facility" and together with the Term Loan, the "Credit Facilities"). The Credit Facilities expire on June 15, 2023. Interest on the Credit Facilities is established using LIBOR plus 1.13% - 1.75%, depending on the Company's leverage ratio. Under the Credit Facilities, the Company is required to maintain certain leverage and interest coverage ratios specified in the credit agreement as well as other customary non-financial affirmative and negative covenants. At December 28, 2019, \$328.1 million was outstanding under the Term Loan with an effective interest rate of 3.0% and \$45.0 million was outstanding on the Revolving Credit Facility. The Company also has \$25.4 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of December 28, 2019.

The Company has required scheduled principal payments of \$4.4 million during the remainder of fiscal 2020, \$21.9 million during fiscal 2021, \$17.5 million during fiscal 2022, \$214.4 million during fiscal 2023 and \$70.0 million thereafter.

The Company was in compliance with the leverage and interest coverage ratios specified in the Credit Facilities as well as all other bank covenants as of December 28, 2019.

13. DERIVATIVES AND FAIR VALUE MEASUREMENTS

The Company manufactures, markets and sells its products globally. During the three and nine months ended December 28, 2019, 35.4% and 35.3%, respectively, of the Company's sales were generated outside the U.S., generally in foreign currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company's reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of the Company's designated foreign currency hedge contracts as of December 28, 2019 and March 30, 2019 were cash flow hedges under ASC 815, *Derivatives and Hedging* ("ASC 815"). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of \$23.1 million as of December 28, 2019 and \$81.5 million as of March 30, 2019. At December 28, 2019, a gain of \$1.2 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of December 28, 2019 mature within twelve months.

Non-Designated Foreign Currency Contracts

The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of \$87.4 million as of December 28, 2019 and \$37.4 million as of March 30, 2019.

Interest Rate Swaps

On June 15, 2018, the Company entered into Credit Facilities which provided for a \$350.0 million Term Loan and a \$350.0 million Revolving Credit Facility. Under the terms of the Credit Facilities, interest is established using LIBOR plus 1.13% - 1.75%. As a result, the Company's earnings and cash flows are exposed to interest rate risk from changes to LIBOR. Part of the Company's interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company's objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

In August 2018, the Company entered into two interest rate swap agreements (the "Swaps") to pay an average fixed rate of 2.80% on a total notional value of \$241.9 million of debt. As a result of the Swaps, 70% of the Term Loan previously exposed to interest rate risk from changes in LIBOR is now fixed at a rate of 4.05%. The Swaps mature on June 15, 2023. The Company designated the Swaps as cash flow hedges of variable interest rate risk associated with \$328.1 million of indebtedness. For the nine months ended December 28, 2019, a loss of \$4.5 million, net of tax, was recorded in accumulated other comprehensive loss to recognize the effective portion of the fair value of the Swaps that qualify as cash flow hedges.

Fair Value of Derivative Instruments

The following table presents the effect of the Company's derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its condensed consolidated statements of income and comprehensive income for the nine months ended December 28, 2019:

<i>(In thousands)</i>	Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss	Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	Location in Condensed Consolidated Statements of Income and Comprehensive Income	Amount of Gain (Loss) Excluded from Effectiveness Testing	Location in Condensed Consolidated Statements of Income and Comprehensive Income
Designated foreign currency hedge contracts, net of tax	\$ 1,224	\$ 401	Net revenues, COGS and SG&A	\$ 481	Interest and other expense, net
Non-designated foreign currency hedge contracts	\$ —	\$ —		\$ (244)	Interest and other expense, net
Designated interest rate swaps, net of tax	\$ (4,506)	\$ (828)	Interest and other expense, net	\$ —	

The Company did not have fair value hedges or net investment hedges outstanding as of December 28, 2019 or March 30, 2019. As of December 28, 2019, no deferred tax assets were recognized for designated foreign currency hedges.

ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, *Fair Value Measurements and Disclosures*, by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, it uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 28, 2019, the Company has classified its derivative

assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.

The following tables present the fair value of the Company's derivative instruments as they appear in its condensed consolidated balance sheets as of December 28, 2019 and March 30, 2019:

<i>(In thousands)</i>	Location in Condensed Consolidated Balance Sheets	As of December 28, 2019	As of March 30, 2019
Derivative Assets:			
Designated foreign currency hedge contracts	Other current assets	\$ 487	\$ 1,208
Non-designated foreign currency hedge contracts	Other current assets	155	69
		<u>\$ 642</u>	<u>\$ 1,277</u>
Derivative Liabilities:			
Designated foreign currency hedge contracts	Other current liabilities	\$ 11	\$ 145
Non-designated foreign currency hedge contracts	Other current liabilities	481	—
Designated interest rate swaps	Other current liabilities	8,476	5,203
		<u>\$ 8,968</u>	<u>\$ 5,348</u>

Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:

- Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
- Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
- Level 3 — Inputs to the valuation methodology are unobservable inputs based on management's best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company's money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 28, 2019 and March 30, 2019.

<i>(In thousands)</i>	As of December 28, 2019		
	Level 1	Level 2	Total
Assets			
Money market funds	\$ 30,281	\$ —	\$ 30,281
Designated foreign currency hedge contracts	—	487	487
Non-designated foreign currency hedge contracts	—	155	155
	<u>\$ 30,281</u>	<u>\$ 642</u>	<u>\$ 30,923</u>
Liabilities			
Designated foreign currency hedge contracts	\$ —	\$ 11	\$ 11
Non-designated foreign currency hedge contracts	—	481	481
Designated interest rate swaps	—	8,476	8,476
	<u>\$ —</u>	<u>\$ 8,968</u>	<u>\$ 8,968</u>
As of March 30, 2019			
	Level 1	Level 2	Total
Assets			
Money market funds	\$ 36,980	\$ —	\$ 36,980
Designated foreign currency hedge contracts	—	1,208	1,208
Non-designated foreign currency hedge contracts	—	69	69
	<u>\$ 36,980</u>	<u>\$ 1,277</u>	<u>\$ 38,257</u>
Liabilities			
Designated foreign currency hedge contracts	\$ —	\$ 145	\$ 145
Designated interest rate swaps	—	5,203	5,203
	<u>\$ —</u>	<u>\$ 5,348</u>	<u>\$ 5,348</u>

Other Fair Value Disclosures

The Term Loan, which is carried at amortized cost, accounts receivable and accounts payable approximate fair value.

14. COMMITMENTS AND CONTINGENCIES

The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on the financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, *Contingencies*, for all matters. Legal costs are expensed as incurred.

Litigation and Related Matters

Product Recall

In August 2018, the Company issued a voluntary recall of certain whole blood collection kits sold to its Blood Center customers in the U.S. The recall resulted from some collection sets' filters failing to adequately remove leukocytes from collected blood. As a result of the recall, the Company's Blood Center customers may have conducted tests to confirm that the collected blood was adequately leukoreduced, sold the collected blood labeled as non-leukoreduced at a lower price or discarded the collected blood. As of December 28, 2019, the Company has recorded cumulative charges of \$1.9 million associated with this recall which consists of \$0.1 million of charges associated with customer returns and inventory reserves

and \$1.8 million of charges associated with customer claims. Substantially all outstanding claims have been paid as of December 28, 2019.

15. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, the Company's operating segments were based primarily on geography. Effective as of March 31, 2019, the Company completed the transition of its operating structure to three global business units and accordingly, reorganized its reporting structure to align with its three global business units and the information that will be regularly reviewed by the Company's chief operating decision maker.

Following the reorganization, the Company's reportable segments are as follows:

- Plasma
- Blood Center
- Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, accelerated depreciation, gains and losses on asset dispositions, certain transaction costs and legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:

	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
<i>(In thousands)</i>				
Net revenues				
Plasma	\$ 120,997	\$ 112,738	\$ 348,141	\$ 318,878
Blood Center	85,314	84,775	246,977	248,106
Hospital	50,753	47,410	147,602	140,686
Net revenues by business unit	257,064	244,923	742,720	707,670
Service ⁽¹⁾	5,197	4,875	15,339	13,937
Effect of exchange rates	(3,291)	(2,442)	(8,072)	(3,323)
Net revenues	\$ 258,970	\$ 247,356	\$ 749,987	\$ 718,284

⁽¹⁾ Reflects revenue for service, maintenance and parts

(In thousands)	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
Segment operating income				
Plasma	\$ 59,343	\$ 47,133	\$ 169,844	\$ 133,661
Blood Center	42,197	41,478	121,124	121,005
Hospital	20,593	18,163	60,360	56,006
Segment operating income	122,133	106,774	351,328	310,672
Corporate expenses ⁽¹⁾	(63,080)	(66,229)	(188,363)	(196,178)
Effect of exchange rates	2,521	2,133	7,791	7,782
Impairment of assets and other related charges	—	—	(51,220)	(21,170)
Deal amortization	(5,772)	(6,131)	(17,681)	(18,667)
PCS2 accelerated depreciation and related costs	(6,649)	(4,822)	(18,708)	(13,203)
Gain on sale of assets	—	—	8,083	—
Restructuring and turnaround costs	(7,798)	(1,791)	(13,582)	(7,258)
European Medical Device Regulation costs	(448)	—	(1,005)	—
Legal Charges	—	(1,614)	701	(2,289)
Operating income	\$ 40,907	\$ 28,320	\$ 77,344	\$ 59,689

⁽¹⁾ Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company's product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:

(In thousands)	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
Plasma products and services	\$ 141,231	\$ 131,823	\$ 406,825	\$ 373,078
Blood Center products and services	66,126	67,155	191,648	199,881
Hospital products and services	51,613	48,378	151,514	145,325
Net revenues	\$ 258,970	\$ 247,356	\$ 749,987	\$ 718,284

Net revenues generated in the Company's principle operating regions on a reported basis are as follows:

(In thousands)	Three Months Ended		Nine Months Ended	
	December 28, 2019	December 29, 2018	December 28, 2019	December 29, 2018
United States	\$ 167,238	\$ 157,457	\$ 485,493	\$ 452,523
Japan	19,268	17,734	55,111	52,295
Europe	40,984	40,977	115,811	119,075
Asia	29,436	29,166	88,269	89,136
Other	2,044	2,022	5,303	5,255
Net revenues	\$ 258,970	\$ 247,356	\$ 749,987	\$ 718,284

16. ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of Accumulated Other Comprehensive Loss are as follows:

<i>(In thousands)</i>	Foreign Currency	Defined Benefit Plans	Net Unrealized Gain/Loss on Derivatives	Total
Balance as of March 30, 2019	\$ (25,513)	\$ (527)	\$ (4,340)	\$ (30,380)
Other comprehensive loss before reclassifications ⁽¹⁾	(470)	—	(3,282)	(3,752)
Amounts reclassified from Accumulated Other Comprehensive Loss ⁽¹⁾	—	—	427	427
Net current period other comprehensive loss	(470)	—	(2,855)	(3,325)
Balance as of December 28, 2019	<u>\$ (25,983)</u>	<u>\$ (527)</u>	<u>\$ (7,195)</u>	<u>\$ (33,705)</u>

⁽¹⁾ Presented net of income taxes, the amounts of which are insignificant.

17. SUBSEQUENT EVENT

On January 13, 2020, the Company purchased the technology underlying the TEG[®] 6s Hemostasis Analyzer System from Cora Healthcare, Inc. and CoraMed Technologies, LLC (the "Cora Parties"). In connection with this transaction, the Company acquired ownership of intellectual property previously licensed from the Cora Parties on an exclusive basis in the field of hospitals and hospital laboratories. This acquisition will allow the Company to pursue site of care opportunities beyond the hospital setting. The intangible asset acquired as a result of this transaction will be recorded during the fourth quarter of fiscal 2020 in the Company's Hospital business unit.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read in conjunction with both our interim condensed consolidated financial statements and notes thereto which appear elsewhere in this Quarterly Report on Form 10-Q and our annual consolidated financial statements, notes thereto and the MD&A contained in our Annual Report on Form 10-K for the fiscal year ended March 30, 2019. The following discussion may contain forward-looking statements and should be read in conjunction with the "Cautionary Statement Regarding Forward-Looking Information" in this discussion.

Introduction

Haemonetics is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions to customers to help improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets including blood and plasma component collection, the surgical suite, and hospital transfusion services. When used in this report, the terms "we," "us," "our" and the "Company" mean Haemonetics.

Our products are organized into three categories for purposes of evaluating and developing their growth potential: Plasma, Blood Center and Hospital. For that purpose, "Plasma" includes plasma collection devices and disposables, plasma donor management software and anticoagulant and saline sold to commercial plasma customers that collect plasma primarily for further fractionation into plasma-derived biopharmaceuticals. "Blood Center" includes blood collection and processing devices and disposables for apheresis (red cells, platelets and plasma) and whole blood that are used primarily for transfusion purposes as well as donor management software. "Hospital", which is comprised of Hemostasis Management, Cell Salvage and Transfusion Management products, includes devices and methodologies for measuring coagulation characteristics of blood, surgical blood salvage systems, specialized blood cell processing systems and disposables and blood transfusion management software.

Plasma and Hospital have growth potential, while Blood Center competes in challenging markets which require us to manage the business differently, including reducing costs, rationalizing the current product line, and evaluating opportunities to exit unfavorable customer contracts.

Recent Developments

Acquisition

On January 13, 2020, we purchased the technology underlying the TEG[®] 6s Hemostasis Analyzer System from Cora Healthcare, Inc. and CoraMed Technologies, LLC (the "Cora Parties"). In connection with this transaction, we acquired ownership of intellectual property previously licensed from the Cora Parties on an exclusive basis in the field of hospitals and hospital laboratories. This acquisition will allow us to pursue site of care opportunities beyond the hospital setting.

Divestiture

On May 21, 2019, we transferred to CSL Plasma Inc. ("CSL") substantially all of the tangible assets held by Haemonetics relating to the manufacture of anti-coagulant and saline at our Union, South Carolina facility and CSL assumed certain related liabilities pursuant to the terms of a settlement, release and asset transfer agreement between the parties dated May 13, 2019. At the closing, we received \$9.8 million of proceeds and were concurrently released from our obligations to supply liquid solutions under a 2014 supply agreement with CSL. We will continue to supply liquid solutions to our customers following the asset transfer agreement pursuant to our supplier arrangements with contract manufacturers. We recognized an asset impairment in the first quarter of fiscal 2020 of \$48.7 million as a result of this transaction.

Share Repurchase Program

In May 2019, the Company's Board of Directors authorized the repurchase of up to \$500 million of Haemonetics common shares over the next two years.

In July 2019, the Company completed a \$75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement ("ASR") entered into with Citibank N.A. ("Citibank") in June 2019. The total number of shares repurchased under the ASR was 0.6 million at an average price per share upon final settlement of \$116.33.

In October 2019, the Company completed an additional \$50.0 million repurchase of its common stock pursuant to an ASR entered into with Morgan Stanley & Co. LLC ("Morgan Stanley") in September 2019. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of \$124.37.

In December 2019, the Company entered into an ASR with Bank of America, N.A. ("Bank of America") to repurchase \$50.0 million of the Company's common stock. Pursuant to the terms of the ASR, in December 2019, the Company paid Bank of America \$50.0 million in cash and received an initial delivery of 0.3 million shares of the Company's common stock based on a closing market price on the New York Stock Exchange on December 11, 2019 of \$117.55. This initial delivery of shares represented approximately 80% of the notional amount of the ASR. On January 23, 2020, the ASR was completed and an additional 0.1 million shares were delivered upon settlement. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of \$114.73.

As of December 28, 2019, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was \$325 million.

Restructuring Program

In July 2019, our Board of Directors approved a new Operational Excellence Program (the "2020 Program") and delegated authority to management to determine the detail of the initiatives that will comprise the program. The 2020 Program is designed to improve operational performance and reduce cost principally in our manufacturing and supply chain operations. We estimate that we will incur aggregate charges between \$60 million and \$70 million in connection with the 2020 Program. These charges, the majority of which will result in cash outlays, including severance and other employee costs, will be incurred as the specific actions required to execute these initiatives are identified and approved and are expected to be substantially completed by the end of fiscal 2023. Savings from the 2020 Program are targeted to reach \$80 million to \$90 million on an annualized basis once the program is completed. During the three and nine months ended December 28, 2019, we incurred \$3.9 million and \$6.8 million, respectively, of restructuring and turnaround costs under this program.

Relocation of Corporate Headquarters

In December 2018, we entered into a lease for office space in Boston, MA to serve as our new corporate headquarters and replace our prior corporate headquarters located in Braintree, MA. During the second quarter of fiscal 2020, we sold \$7.8 million of real estate and other assets associated with the Braintree corporate headquarters and entered into a lease with the buyer that allowed the Company to leaseback that facility on a rent-free basis through December 31, 2019 until the completion of its relocation to Boston, MA, which occurred during the third quarter of fiscal 2020. As a result of this transaction, we received net cash proceeds of \$15.0 million and non-cash consideration of \$0.9 million related to a free rent period ending in December 2019. The transaction resulted in a net gain of \$8.1 million.

Change in Reportable Segments

Effective March 31, 2019, we completed the transition of our operating structure to three global business units - Plasma, Blood Center and Hospital - and accordingly reorganized our operating and reporting structure to align with our three global business units. This new segment structure has been realigned in accordance with the respective markets to accurately reflect the ongoing performance of each business and excludes service. The discussion of our results of operations that follows has been revised to reflect our new reportable segments.

Financial Summary

	Three Months Ended			Nine Months Ended		
	December 28, 2019	December 29, 2018	% Increase/ (Decrease)	December 28, 2019	December 29, 2018	% Increase/ (Decrease)
<i>(In thousands, except per share data)</i>						
Net revenues	\$ 258,970	\$ 247,356	4.7%	\$ 749,987	\$ 718,284	4.4 %
Gross profit	\$ 128,050	\$ 111,175	15.2%	\$ 370,956	\$ 306,326	21.1 %
<i>% of net revenues</i>	49.4%	44.9%		49.5%	42.6%	
Operating expenses	\$ 87,143	\$ 82,855	5.2%	\$ 293,612	\$ 246,637	19.0 %
Operating income	\$ 40,907	\$ 28,320	44.4%	\$ 77,344	\$ 59,689	29.6 %
<i>% of net revenues</i>	15.8%	11.4%		10.3%	8.3%	
Interest and other expense, net	\$ (3,078)	\$ (2,858)	7.7%	\$ (12,152)	\$ (7,875)	54.3 %
Income before provision for income taxes	\$ 37,829	\$ 25,462	48.6%	\$ 65,192	\$ 51,814	25.8 %
Provision for income taxes	\$ 7,934	\$ 7,185	10.4%	\$ 6,290	\$ 17,630	(64.3)%
<i>% of pre-tax income</i>	21.0%	28.2%		9.6%	34.0%	
Net income	\$ 29,895	\$ 18,277	63.6%	\$ 58,902	\$ 34,184	72.3 %
<i>% of net revenues</i>	11.5%	7.4%		7.9%	4.8%	
Net income per share - basic	\$ 0.59	\$ 0.36	63.9%	\$ 1.16	\$ 0.66	75.8 %
Net income per share - diluted	\$ 0.58	\$ 0.35	65.7%	\$ 1.13	\$ 0.64	76.6 %

Net revenues increased 4.7% and 4.4% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Without the effect of foreign exchange, net revenues increased 5.0% and 5.1% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Revenue increases in Plasma and Hospital primarily drove the overall increase in revenue during the three and nine months ended December 28, 2019.

Operating income increased for the three and nine months ended December 28, 2019, as compared with the same periods of fiscal 2019, primarily due to favorable pricing, product mix and incremental savings from both the 2020 Program and the Complexity Reduction Initiative (the "2018 Program"). The gain recognized on the sale of real estate and other assets associated with the Braintree corporate headquarters also contributed to the increase during the nine months ended December 28, 2019. Impairment charges associated with the divestiture of our plasma liquid solutions operations to CSL partially offset increases in operating income during the nine months ended December 28, 2019.

Management's Use of Non-GAAP Measures

Management uses non-GAAP financial measures, in addition to financial measures in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency conversion rate. We have provided this non-GAAP financial measure because we believe it provides meaningful information regarding our results on a consistent and comparable basis for the periods presented.

RESULTS OF OPERATIONS

Net Revenues by Geography

(In thousands)	Three Months Ended				
	December 28, 2019	December 29, 2018	Reported growth	Currency impact	Constant currency growth ⁽¹⁾
United States	\$ 167,238	\$ 157,457	6.2%	— %	6.2%
International	91,732	89,899	2.0%	(0.9)%	2.9%
Net revenues	<u>\$ 258,970</u>	<u>\$ 247,356</u>	4.7%	(0.3)%	5.0%

⁽¹⁾ Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See "Management's Use of Non-GAAP Measures."

(In thousands)	Nine Months Ended				
	December 28, 2019	December 29, 2018	Reported growth	Currency impact	Constant currency growth ⁽¹⁾
United States	\$ 485,493	\$ 452,523	7.3 %	— %	7.3%
International	264,494	265,761	(0.5)%	(2.5)%	2.0%
Net revenues	<u>\$ 749,987</u>	<u>\$ 718,284</u>	4.4 %	(0.7)%	5.1%

⁽¹⁾ Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See "Management's Use of Non-GAAP Measures."

Our principal operations are in the U.S., Europe, Japan and other parts of Asia. Our products are marketed in approximately 90 countries around the world through a combination of our direct sales force, independent distributors and agents. Our revenue generated outside the U.S. was 35.4% and 35.3% of total net revenues for the three and nine months ended December 28, 2019, respectively, as compared with 36.3% and 37.0% for the three and nine months ended December 29, 2018, respectively. International sales are generally conducted in local currencies, primarily Japanese Yen, Euro, Chinese Yuan and Australian Dollars. Our results of operations are impacted by changes in foreign exchange rates, particularly in the value of the Yen, Euro and Australian Dollar relative to the U.S. Dollar. We have placed foreign currency hedges to mitigate our exposure to foreign currency fluctuations.

Please see the section entitled "Foreign Exchange" in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure.

Net Revenues by Business Unit

(In thousands)	Three Months Ended				
	December 28, 2019	December 29, 2018	Reported growth	Currency impact	Constant currency growth ⁽¹⁾
Plasma	\$ 120,420	\$ 112,659	6.9%	(0.4)%	7.3%
Blood Center	83,411	82,846	0.7%	0.1 %	0.6%
Hospital ⁽²⁾	50,266	47,233	6.4%	(0.7)%	7.1%
Service	4,873	4,618	5.5%	(1.1)%	6.6%
Net revenues	<u>\$ 258,970</u>	<u>\$ 247,356</u>	4.7%	(0.3)%	5.0%

⁽¹⁾ Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See "Management's Use of Non-GAAP Measures."

⁽²⁾ Hospital revenue includes Hemostasis Management revenue of \$24.7 million and \$20.8 million for the three months ended December 28, 2019 and December 29, 2018, respectively. Hemostasis Management revenue increased 18.6% in the third quarter of fiscal 2020 as compared with the same period of fiscal 2019. Without the effect of foreign exchange, Hemostasis Management revenue increased 19.8% in the third quarter of fiscal 2020 as compared with the same period of fiscal 2019.

<i>(In thousands)</i>	Nine Months Ended				
	December 28, 2019	December 29, 2018	Reported growth	Currency impact	Constant currency growth ⁽¹⁾
Plasma	\$ 346,767	\$ 318,824	8.8 %	(0.4)%	9.2 %
Blood Center	241,196	243,938	(1.1)%	(0.6)%	(0.5)%
Hospital ⁽²⁾	147,665	142,195	3.8 %	(1.1)%	4.9 %
Service	14,359	13,327	7.7 %	(2.4)%	10.1 %
Net revenues	\$ 749,987	\$ 718,284	4.4 %	(0.7)%	5.1 %

⁽¹⁾ Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See "Management's Use of Non-GAAP Measures."

⁽²⁾ Hospital revenue includes Hemostasis Management revenue of \$73.9 million and \$64.0 million for the nine months ended December 28, 2019 and December 29, 2018, respectively. Hemostasis Management revenue increased 15.4% in the first nine months of fiscal 2020 as compared with the same period of fiscal 2019. Without the effect of foreign exchange, Hemostasis Management revenue increased 17.2% in the first nine months of fiscal 2020 as compared with the same period of fiscal 2019.

Plasma

Plasma revenue increased 6.9% and 8.8% during the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Without the effect of foreign exchange, Plasma revenue increased 7.3% and 9.2% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. This revenue growth was primarily driven by an increase in volume of plasma disposables due to continued strong performance in the United States during the three and nine months ended December 28, 2019. Favorable NexSys PCS pricing and increases in sales of software, partially offset by declines in plasma liquid solutions, also contributed to the overall increase during the three and nine months ended December 28, 2019.

On May 21, 2019, we transferred to CSL substantially all of the tangible assets held by Haemonetics relating to the manufacture of anti-coagulant and saline at our Union, South Carolina facility. We will continue to supply liquid solutions to our customers on an as needed basis using contract manufacturers, however, we expect declines in our plasma liquids revenue beginning in the fourth quarter of fiscal 2020 as we continue to exit this business.

Blood Center

Blood Center revenue increased 0.7% and decreased 1.1% during the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Without the effect of foreign exchange, Blood Center revenue increased 0.6% and decreased 0.5% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. The increase during the three months ended December 28, 2019 was primarily driven by increased sales of apheresis products, partially offset by declines in software revenue and whole blood disposables. The decrease during the nine months ended December 28, 2019 was primarily driven by declines in whole blood disposables and software revenue, partially offset by increases in apheresis products. The favorable impact of the apheresis business during the three and nine months ended December 28, 2019 was primarily driven by order timing, the benefit of which is expected to reverse in the fourth quarter and to be further compounded by additional declines as certain customers convert to alternative sources of supply. The expected impact of the loss of this apheresis business is an incremental revenue decline of approximately \$2 million dollars in the fourth quarter of fiscal 2020 as compared with the fourth quarter of the prior year and \$17 million in fiscal 2021 as compared with fiscal 2020.

Hospital

Hospital revenue increased 6.4% and 3.8% during the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Without the effect of foreign exchange, Hospital revenue increased 7.1% and 4.9% during the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. The increase for both the three and nine months ended December 28, 2019 was primarily attributable to the growth of disposables associated with TEG[®] diagnostic systems, principally in the United States. In May 2019, we received FDA clearance for the use of TEG 6s in adult trauma settings. This clearance builds on the current indication for the TEG 6s system in cardiovascular surgery and cardiology procedures, making it the first cartridge-based system available in the U.S. to evaluate the hemostasis condition in adult trauma patients. The increase during the three and nine months ended December 28, 2019 was partially offset by declines due to the discontinuance of sales of our OrthoPAT products effective March 31, 2019.

Gross Profit

<i>(In thousands)</i>	Three Months Ended			Nine Months Ended		
	December 28, 2019	December 29, 2018	% Increase/ (Decrease)	December 28, 2019	December 29, 2018	% Increase/ (Decrease)
Gross profit	\$ 128,050	\$ 111,175	15.2%	\$ 370,956	\$ 306,326	21.1%
% of net revenues	49.4%	44.9%		49.5%	42.6%	

Gross profit increased 15.2% and 21.1% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Without the effect of foreign exchange, gross profit increased 15.4% and 22.3% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. The increase in gross profit margin during the three and nine months ended December 28, 2019 was primarily due to favorable pricing driven by the annualization of NexSys PCS device conversions, mix and incremental savings from the 2020 Program. The absence of impairment charges that were incurred in the prior year period also contributed to the increase during the nine months ended December 28, 2019.

Operating Expenses

<i>(In thousands)</i>	Three Months Ended			Nine Months Ended		
	December 28, 2019	December 29, 2018	% Increase/ (Decrease)	December 28, 2019	December 29, 2018	% Increase/ (Decrease)
Research and development	\$ 7,000	\$ 8,978	(22.0)%	\$ 21,909	\$ 26,967	(18.8)%
% of net revenues	2.7%	3.6%		2.9%	3.8%	
Selling, general and administrative	\$ 78,267	\$ 73,877	5.9 %	\$ 221,106	\$ 219,670	0.7 %
% of net revenues	30.2%	29.9%		29.5%	30.6%	
Impairment of assets	\$ 1,876	\$ —	100.0 %	\$ 50,597	\$ —	100.0 %
% of net revenues	0.7%	—%		6.7%	—%	
Total operating expenses	\$ 87,143	\$ 82,855	5.2 %	\$ 293,612	\$ 246,637	19.0 %
% of net revenues	33.6%	33.5%		39.1%	34.3%	

Research and Development

Research and development expenses decreased 22.0% and 18.8% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Without the effect of foreign exchange, research and development expenses decreased 22.0% and 18.7% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. The decrease during the three and nine months ended December 28, 2019 was primarily driven by investments made in clinical programs in the prior year period in order to support FDA clearance for the use of TEG 6s in adult trauma settings, which was received in May 2019.

Selling, General and Administrative

Selling, general and administrative expenses increased 5.9% and 0.7% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. Without the effect of foreign exchange, selling, general, and administrative expenses increased 6.5% and 1.5% for the three and nine months ended December 28, 2019, respectively, as compared with the same periods of fiscal 2019. The increase during the three and nine months ended December 28, 2019 was primarily due to an increase in restructuring and turnaround costs, an increase in investments and increases in both share-based compensation and variable compensation expense. These increases were partially offset by incremental savings from both the 2020 Program and the 2018 Program in the current year periods. Additionally, the gain recognized on the sale of assets associated with the Braintree corporate headquarters contributed to the partial offset during the nine months ended December 28, 2019.

Impairment of assets

We recognized impairment charges of \$1.9 million and \$50.6 million for the three and nine months ended December 28, 2019, respectively. The impairment charges during the nine months ended December 28, 2019 were primarily due to the transfer to CSL of substantially all of our tangible assets related to the manufacture of anti-coagulant and saline at our Union, South Carolina facility to CSL. Refer to Note 4, *Divestiture*, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for information pertaining to this agreement. During the three months ended December 28, 2019 we recorded other asset impairments totaling \$1.9 million.

Interest and Other Expense, Net

Interest expense from our \$350.0 million term loan and \$350.0 million revolving loan entered into on June 15, 2018, which constitutes the majority of expense, decreased by \$0.3 million during the three months ended December 29, 2019 due to higher term loan borrowings in the prior year period, partially offset by a decrease in the effective interest rate. Interest expense increased by \$1.4 million during the nine months ended December 28, 2019 due to an increase in the revolving credit facility balance, partially offset by the decrease in the effective interest rate. The effective interest rate on total debt outstanding as of December 28, 2019 was 3.0%.

Income Taxes

We conduct business globally and report our results of operations in a number of foreign jurisdictions in addition to the United States. Our reported tax rate is impacted by the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which we operate have tax rates that differ from the U.S. statutory tax rate.

For the three and nine months ended December 28, 2019, we reported an income tax provision of \$7.9 million and \$6.3 million, respectively, representing an effective tax rate of 21.0% and 9.6%, respectively. The effective tax rate for the three and nine months ended December 28, 2019 includes discrete tax benefits recognized from excess stock compensation deductions of \$3.1 million and \$12.4 million, respectively. The effective tax rates were also impacted by the jurisdictional mix of earnings and the impact of the divestiture of the Union liquid solutions operation in the first quarter of fiscal 2020. Refer to Note 4, *Divestiture*, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for information pertaining to this divestiture.

For the three and nine months ended December 29, 2018, we reported an income tax provision of \$7.2 million and \$17.6 million, representing an effective tax rate of 28.2% and 34.0%, respectively. The tax rate for the three and nine months ended December 29, 2018 includes a discrete stock compensation windfall benefit of \$1.8 million and \$5.8 million, respectively. The effective tax rate for the nine months ended December 29, 2018 was higher than the U.S. statutory tax rate primarily due to an asset impairment of \$21.2 million recorded in pretax income for which no tax benefit was recognized as a result of the valuation allowance maintained against its deferred tax assets in the impacted jurisdiction.

Liquidity and Capital Resources

The following table contains certain key performance indicators we believe depict our liquidity and cash flow position:

<i>(Dollars in thousands)</i>	December 28, 2019	March 30, 2019
Cash & cash equivalents	\$ 126,417	\$ 169,351
Working capital	\$ 325,883	\$ 340,362
Current ratio	2.3	2.4
Net debt ⁽¹⁾	\$ (245,287)	\$ (180,769)
Days sales outstanding (DSO)	59	67
Inventory turnover	1.9	2.5

⁽¹⁾Net debt position is the sum of cash and cash equivalents less total debt.

In July 2019, our Board of Directors approved the 2020 Program. We estimate that we will incur aggregate charges between \$60 million and \$70 million in connection with the 2020 Program. These charges, the majority of which will result in cash outlays, including severance and other employee costs, will be incurred as the specific actions required to execute these initiatives are identified and approved and are expected to be substantially completed by the end of fiscal 2023. During the three and nine months ended December 28, 2019, the Company incurred \$3.9 million and \$6.8 million, respectively, of restructuring and turnaround costs under this program.

Our primary sources of liquidity are cash and cash equivalents, internally generated cash flow from operations, our Revolving Credit Facility and proceeds from employee stock option exercises. We believe these sources are sufficient to fund our cash requirements over at least the next twelve months. Our expected cash outlays relate primarily to investments, capital expenditures, including production of the NexSys PCS and Plasma plant capacity expansions, share repurchases, cash payments under the loan agreement and restructuring and turnaround initiatives.

As of December 28, 2019, we had \$126.4 million in cash and cash equivalents, the majority of which is held in the U.S. or in countries from which it can be repatriated to the U.S. On June 15, 2018, we entered into a five-year credit agreement which provided for a \$350.0 million term loan and a \$350.0 million revolving loan. Interest on the term loan and revolving loan is established using LIBOR plus 1.13% - 1.75%, depending on our leverage ratio. Under the Credit Facilities, we are required to maintain certain leverage and interest coverage ratios specified in the credit agreement as well as other customary non-financial affirmative and negative covenants. At December 28, 2019, \$328.1 million was outstanding under the Term Loan with an effective interest rate of 3.0% and \$45.0 million was outstanding on the Revolving Credit Facility. We also had \$25.4 million of uncommitted operating lines of credit to fund our global operations under which there were no outstanding borrowings as of December 28, 2019.

We have scheduled principal payments of \$4.4 million required during the remainder of fiscal 2020. We were in compliance with the leverage and interest coverage ratios specified in the credit agreement as well as all other bank covenants as of December 28, 2019.

Cash Flows

<i>(In thousands)</i>	Nine Months Ended		
	December 28, 2019	December 29, 2018	Increase/ (Decrease)
Net cash provided by (used in):			
Operating activities	\$ 111,811	\$ 138,643	\$ (26,832)
Investing activities	(12,041)	(102,931)	90,890
Financing activities	(142,580)	(57,623)	(84,957)
Effect of exchange rate changes on cash and cash equivalents ⁽¹⁾	(124)	(3,387)	3,263
Net change in cash and cash equivalents	\$ (42,934)	\$ (25,298)	

⁽¹⁾The balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. Dollars. In accordance with U.S. GAAP, we have removed the effect of foreign currency throughout our cash flow statement, except for its effect on our cash and cash equivalents.

Net cash provided by operating activities decreased by \$26.8 million during the nine months ended December 28, 2019, as compared with the nine months ended December 29, 2018. The decrease in cash provided by operating activities was primarily due to a working capital outflow driven largely by an increase in inventory build to support the launch of the NexSys PCS devices, a decrease in accounts payable and accrued payroll and the impact of net income, as adjusted for depreciation, amortization and other non-cash charges. The working capital outflow was partially offset by a decrease in accounts receivable due to the timing of collections.

Net cash used in investing activities decreased by \$90.9 million during the nine months ended December 28, 2019, as compared with the nine months ended December 29, 2018. The decrease in cash used in investing activities was primarily the result of a decrease in capital expenditures in the current year period due to spend related to the NexSys PCS launch and manufacturing capacity expansion projects in our Plasma business in the prior year period. Proceeds received related to the divestiture of our plasma liquid solutions operations and sale of real estate and other assets associated with the Braintree corporate headquarters in the current period also contributed to the decrease in cash used in investing activities during the nine months ended December 28, 2019.

Net cash used in financing activities increased by \$85.0 million during the nine months ended December 28, 2019, as compared with the nine months ended December 29, 2018, primarily due to lower borrowings, net of payments, on our Credit Facilities and by increased share repurchases in the current period.

Concentration of Credit Risk

Concentrations of credit risk with respect to trade accounts receivable are generally limited due to our large number of customers and their diversity across many geographic areas. Certain markets and industries, however, can expose us to concentrations of credit risk. For example, in the Plasma business unit, sales are concentrated with several large customers. As a result, accounts receivable extended to any one of these biopharmaceutical customers can be significant at any point in time. In addition, a portion of our trade accounts receivable outside the U.S. include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays and local economic conditions. Payment is dependent upon the financial stability and creditworthiness of those countries' national economies.

We have not incurred significant losses on receivables. We continually evaluate all receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries' healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Inflation

We do not believe that inflation had a significant impact on our results of operations for the periods presented. Historically, we believe we have been able to mitigate the effects of inflation by improving our manufacturing and purchasing efficiencies, by increasing employee productivity and by adjusting the selling prices of products. We continue to monitor inflation pressures generally and raw materials indices that may affect our procurement and production costs. Increases in the price of petroleum derivatives could result in corresponding increases in our costs to procure plastic raw materials.

Foreign Exchange

During the three and nine months ended December 28, 2019, 35.4% and 35.3%, respectively, of our sales were generated outside the U.S., generally in foreign currencies, yet our reporting currency is the U.S. Dollar. We also incur certain manufacturing, marketing and selling costs in international markets in local currency. Our primary foreign currency exposures relate to sales denominated in Euro, Japanese Yen, Chinese Yuan and Australian Dollars. We also have foreign currency exposure related to manufacturing and other operational costs denominated in Swiss Francs, Canadian Dollars, Mexican Pesos and Malaysian Ringgit. The Yen, Euro, Yuan and Australian Dollar sales exposure is partially mitigated by costs and expenses for foreign operations and sourcing products denominated in foreign currencies.

Since our foreign currency denominated Yen, Euro, Yuan and Australian Dollar sales exceed the foreign currency denominated costs, whenever the U.S. Dollar strengthens relative to the Yen, Euro, Yuan or Australian Dollar, there is an adverse effect on our results of operations and, conversely, whenever the U.S. Dollar weakens relative to the Yen, Euro, Yuan or Australian Dollar, there is a positive effect on our results of operations. For Swiss Francs, Canadian Dollars Mexican Pesos and Malaysian Ringgit our primary cash flows relate to product costs or costs and expenses of local operations. Whenever the U.S. Dollar strengthens relative to these foreign currencies, there is a positive effect on our results of operations. Conversely, whenever the U.S. Dollar weakens relative to these currencies, there is an adverse effect on our results of operations.

We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize forward foreign currency contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent Swiss Francs, Australian Dollars, Canadian Dollars and Mexican Pesos. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. These contracts are designated as cash flow hedges. The final impact of currency fluctuations on the results of operations is dependent on the local currency amounts hedged and the actual local currency results.

Recent Accounting Pronouncements

Standards to be Implemented

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326). ASC Update No. 2016-13 is intended to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. ASC Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, and is applicable to us in fiscal 2021. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles, Goodwill and Other - Internal-Use Software (Subtopic 350-40). The new guidance will align the accounting implementation costs incurred in a cloud computing arrangement that is a service contract with the accounting for internal-use software licenses. The guidance is effective for annual periods beginning after December 15, 2019 and is applicable to us in fiscal 2021. Early adoption is permitted for all entities, including interim periods. The impact of adopting ASC Update No. 2018-15 is not expected to have a material effect on our condensed consolidated financial statements.

In December 2019, the FASB issued ASC Update No. 2019-12, Income Taxes (Topic 740). The new guidance will improve consistent application of and simplify the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. ASC Update No. 2019-12 is effective for annual periods beginning after December 15, 2020, and is applicable to us in fiscal 2022. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.

Cautionary Statement Regarding Forward-Looking Information

Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q and incorporated by reference into this report, constitute "forward looking-statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; the Company's strategy for growth; product development, commercialization and anticipated performance and benefits; regulatory approvals; the impact and timing of restructuring initiatives including associated cost savings and other benefits; the impact of planned acquisitions or dispositions; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company's actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements.

Set forth below are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of these and other factors, see Part I, Item 1A. *Risk Factors* in our most recent Annual Report on Form 10-K.

- Failure to achieve our long-term strategic and financial-improvement goals;
- Demand for and market acceptance risks for new and existing products, including material reductions in purchasing from or loss of a significant customer;
- Product quality or safety concerns, leading to product recalls, withdrawals, regulatory action by the FDA (or similar non-U.S. regulatory agencies), reputational damage, declining sales or litigation;
- Security breaches of our information technology systems or our products, which could impair our ability to conduct business or compromise sensitive information of the Company or its customers, suppliers and other business partners, or of customers' patients and donors;
- Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers and other market participants;
- The continuity, availability and pricing of plastic and other raw materials, finished goods and components used in the manufacturing of our products (including those purchased from sole-source suppliers) and the related continuity of our manufacturing and distribution;
- Our ability to develop new products or enhancements on commercially acceptable terms or at all;
- The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected;
- Our ability to obtain regulatory approvals in a timely manner consistent with cost estimates;
- Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including the U.S. Foreign Corrupt Practices Act, or FCPA, and similar laws in other jurisdictions, as well as U.S. and foreign export and import restrictions and tariffs;
- Our ability to execute and realize anticipated benefits from our investments in emerging economies;
- Our ability to obtain the anticipated benefits of restructuring programs that we have or may undertake, including the 2020 Program and 2018 Program;
- Our ability to retain and attract key personnel;
- Costs and risks associated with product liability and other litigation claims;
- Our ability to meet our existing debt obligations and raise additional capital when desired on terms reasonably acceptable to us;
- The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, expenses and resulting margins;
- The impact of changes in U.S. and international tax laws;
- Market conditions and the possibility that the Company's share repurchase program may be delayed, suspended or discontinued;
- The effect of communicable diseases on demand for our products; and
- Our ability to protect intellectual property and the outcome of patent litigation.

Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in our Part I, Item 1A. *Risk Factors* in our Annual Report on Form 10-K to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our exposure relative to market risk is due to foreign exchange risk and interest rate risk.

Foreign Exchange Risk

See the section above entitled Foreign Exchange for a discussion of how foreign currency affects our business. It is our policy to minimize, for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge anticipated cash flows from forecasted foreign currency denominated sales and costs. We do not use the financial instruments for speculative or trading activities.

We estimate the change in the fair value of all forward contracts assuming both a 10% strengthening and weakening of the U.S. Dollar relative to all other major currencies. In the event of a 10% strengthening of the U.S. Dollar, the change in fair value of all forward contracts would result in a \$9.7 million increase in the fair value of the forward contracts; whereas a 10% weakening of the U.S. Dollar would result in a \$10.8 million decrease of the fair value of the forward contracts.

Interest Rate Risk

Our exposure to changes in interest rates is associated with borrowings under our Credit Facilities, all of which is variable rate debt. Total outstanding debt under our Credit Facilities as of December 28, 2019 was \$328.1 million with an interest rate of 3.0% based on prevailing LIBOR rates. An increase of 100 basis points in LIBOR rates would result in additional annual interest expense of \$1.0 million. On August 21, 2018, we entered into two interest rate swap agreements to effectively convert \$241.9 million of borrowings under our Credit Facilities from a variable rate to a fixed rate. These interest rate swaps are intended to mitigate the exposure to fluctuations in interest rates and qualify for hedge accounting treatment as cash flow hedges.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We conducted an evaluation, as of December 28, 2019, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively) regarding the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15 of the Exchange Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of December 28, 2019.

Changes in Internal Control Over Financial Reporting

We implemented certain controls related to the adoption of FASB ASC Topic 842, effective March 31, 2019. These controls were designed and implemented to ensure the completeness and accuracy over financial reporting. With the exception of the controls implemented for FASB ASC Topic 842, there were no changes in our internal control over financial reporting during the three and nine months ended December 28, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Information with respect to this Item may be found in Note 14, *Commitments and Contingencies* to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Item 1A. Risk Factors

There are no material changes from the Risk Factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended March 30, 2019.

Item 2. Issuer Purchases of Equity Securities

The following table provides information on the Company's share repurchases during the third quarter of fiscal 2020:

	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program ⁽¹⁾
September 29, 2019 - October 26, 2019	70,720	⁽²⁾	70,720	
October 27, 2019 - November 23, 2019				
November 24, 2019 - December 28, 2019	340,425	⁽³⁾	340,425	
Total	411,145			\$325,000,000

⁽¹⁾ In May 2019, the Company announced that the Board of Directors had authorized the repurchase of up to \$500 million of the Company's common stock from time to time, based on market conditions, over the next two years. Under the Company's share repurchase program, shares may be repurchased in accordance with applicable laws both on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Exchange Act, and in privately negotiated transactions.

⁽²⁾ In October 2019, the Company completed a \$50.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement ("ASR") entered into with Morgan Stanley & Co. LLC ("Morgan Stanley") in September 2019. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of \$124.37.

⁽³⁾ In December 2019, the Company entered into an ASR with Bank of America, N.A. ("Bank of America") to repurchase \$50.0 million of the Company's common stock. Pursuant to the terms of the ASR, in December 2019, the Company paid Bank of America \$50.0 million in cash and received an initial delivery of 0.3 million shares of the Company's common stock based on a closing market price on the New York Stock Exchange on December 11, 2019 of \$117.55. This initial delivery of shares represented approximately 80% of the notional amount of the ASR. On January 23, 2020, the ASR was completed and an additional 0.1 million shares were delivered upon settlement. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of \$114.73.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

- [31.1](#) Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Christopher A. Simon, President and Chief Executive Officer of the Company.
- [31.2](#) Certification pursuant to Section 302 of Sarbanes-Oxley of 2002, of William Burke, Executive Vice President, Chief Financial Officer of the Company.
- [32.1](#) Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Christopher A. Simon, President and Chief Executive Officer of the Company.
- [32.2](#) Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of William Burke, Executive Vice President, Chief Financial Officer of the Company.
- 101** The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended December 28, 2019, formatted in inline Extensible Business Reporting Language (XBRL) includes: (i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).

** In accordance with Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, is deemed not filed for the purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HAEMONETICS CORPORATION

February 4, 2020 By: /s/ Christopher A. Simon
Christopher A. Simon,
President and Chief Executive Officer
(Principal Executive Officer)

February 4, 2020 By: /s/ William Burke
William Burke, Executive Vice President, Chief Financial
Officer
(Principal Financial Officer)

CERTIFICATION

I, Christopher A. Simon, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Haemonetics Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

February 4, 2020

/s/ Christopher A. Simon

Christopher A. Simon, President and Chief Executive Officer
(Principal Executive Officer)

CERTIFICATION

I, William Burke, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Haemonetics Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

February 4, 2020

/s/ William Burke

William Burke, Executive Vice President, Chief Financial Officer
(Principal Financial Officer)

Certification Pursuant To
18 USC. Section 1350,
As Adopted Pursuant To
Section 906 of the Sarbanes/Oxley Act of 2002

In connection with the Quarterly Report of Haemonetics Corporation (the "Company") on Form 10-Q for the period ended December 28, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christopher A. Simon, President and Chief Executive Officer of the Company, certify, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that this Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

February 4, 2020

/s/ Christopher A. Simon

Christopher A. Simon,
President and Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Haemonetics and will be retained by Haemonetics and furnished to the Securities and Exchange Commission or its staff upon request.

Certification Pursuant To
18 USC. Section 1350,
As Adopted Pursuant To
Section 906 of the Sarbanes/Oxley Act of 2002

In connection with the Quarterly Report of Haemonetics Corporation (the "Company") on Form 10-Q for the period ended December 28, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, William Burke, Executive Vice President, Chief Financial Officer of the Company, certify, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that this Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

February 4, 2020

/s/ William Burke

William Burke,

Executive Vice President, Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Haemonetics and will be retained by Haemonetics and furnished to the Securities and Exchange Commission or its staff upon request.